| scholarly article | Q13442814 |
| P50 | author | Pedro Fonte | Q56937554 |
| P2093 | author name string | Araújo F | |
| Fonte P | |||
| Santos HA | |||
| Sarmento B | |||
| P2860 | cites work | Helodermin-loaded nanoparticles: Characterization and transport across an in vitro model of the follicle-associated epithelium | Q64217941 |
| Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice | Q73193784 | ||
| The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo | Q73727591 | ||
| Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability | Q79283090 | ||
| An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells | Q79754770 | ||
| Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles | Q80814611 | ||
| Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency | Q81097907 | ||
| Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery | Q83019168 | ||
| PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice | Q83061828 | ||
| pH-sensitive nanoparticles self-assembled from a novel class of biodegradable amphiphilic copolymers based on chitosan | Q83163613 | ||
| Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles | Q83387798 | ||
| Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects | Q83392390 | ||
| GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1 | Q83940279 | ||
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Global estimates of the prevalence of diabetes for 2010 and 2030 | Q29547218 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions | Q29617847 | ||
| Physicochemical characterization of degradable thermosensitive polymeric micelles | Q30967633 | ||
| Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles | Q31003996 | ||
| A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice | Q33268721 | ||
| Intestinal absorption of water-soluble vitamins in health and disease | Q33725184 | ||
| GLP-1 for type 2 diabetes | Q33794098 | ||
| A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo | Q33929976 | ||
| Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. | Q34014526 | ||
| Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function | Q34109995 | ||
| Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability | Q34180791 | ||
| A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. | Q34217121 | ||
| Novel Glucagon-like Peptide-1 Analog Delivered Orally Reduces Postprandial Glucose Excursions in Porcine and Canine Models | Q34420048 | ||
| In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods | Q34439443 | ||
| Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: A study of the hSMVT system | Q34564505 | ||
| Protein drug oral delivery: the recent progress | Q34998207 | ||
| Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass | Q35055522 | ||
| Emerging Trends in Oral Delivery of Peptide and Protein Drugs | Q35570636 | ||
| Small-molecule agonists for the glucagon-like peptide 1 receptor | Q35612392 | ||
| Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers | Q35877982 | ||
| Future therapy of diabetes mellitus | Q35978997 | ||
| Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium | Q36090914 | ||
| Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery | Q36320763 | ||
| GLP-1 based therapy for type 2 diabetes | Q36401059 | ||
| Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. | Q36535786 | ||
| Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. | Q36583753 | ||
| Is the oral route possible for peptide and protein drug delivery? | Q36601912 | ||
| Peptide drug delivery strategies for the treatment of diabetes | Q36730601 | ||
| Therapy in the Early Stage: Incretins | Q36783865 | ||
| Current challenges in non-invasive insulin delivery systems: a comparative review | Q36946206 | ||
| Cell and molecular aspects of human intestinal biotin absorption | Q37105800 | ||
| Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues | Q37153923 | ||
| Eligen insulin--a system for the oral delivery of insulin for diabetes. | Q37176179 | ||
| Potential of liraglutide in the treatment of patients with type 2 diabetes. | Q37479037 | ||
| Glycaemic control in type 2 diabetes: targets and new therapies | Q37636745 | ||
| Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? | Q37792839 | ||
| Diabetes mellitus: new drugs for a new epidemic | Q37879307 | ||
| Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment | Q37888162 | ||
| GLP-1 receptor agonists today | Q37902330 | ||
| Predicting oral drug absorption and hepatobiliary clearance: Human intestinal and hepatic in vitro cell models | Q37904308 | ||
| Cardiovascular Effects of Glucagonlike peptide–1 Agonists | Q37908526 | ||
| Regulation of glucagon secretion by incretins | Q37913515 | ||
| Targeting receptors, transporters and site of absorption to improve oral drug delivery | Q37928909 | ||
| Enterocytes’ tight junctions: From molecules to diseases | Q37970075 | ||
| Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments | Q37972427 | ||
| pH-Responsive Nanoparticles Shelled with Chitosan for Oral Delivery of Insulin: From Mechanism to Therapeutic Applications | Q37974960 | ||
| The Oral Delivery of Proteins Using Interpolymer Polyelectrolyte Complexes | Q38029657 | ||
| Opportunities and Challenges for Oral Delivery of Hydrophobic Versus Hydrophilic Peptide and protein-like Drugs Using lipid-based Technologies | Q38029660 | ||
| Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates | Q38514102 | ||
| Novel biodegradable and pH-sensitive poly(ester amide) microspheres for oral insulin delivery | Q39390938 | ||
| A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres | Q39818083 | ||
| New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins | Q42078124 | ||
| Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications | Q42231156 | ||
| Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. | Q42459339 | ||
| Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats | Q43125024 | ||
| Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect | Q43288016 | ||
| No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose | Q43544031 | ||
| Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide | Q43702234 | ||
| Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats | Q44923726 | ||
| Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration | Q44948618 | ||
| A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice | Q46269886 | ||
| Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers | Q46428114 | ||
| Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo | Q46779585 | ||
| Oral delivery of insulin with the eligen technology: mechanistic studies | Q46817835 | ||
| Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery | Q46851809 | ||
| PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice | Q46885178 | ||
| Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | Q46975451 | ||
| Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects | Q48189009 | ||
| Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. | Q48218648 | ||
| Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm | Q51592894 | ||
| The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. | Q53248732 | ||
| Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. | Q53864082 | ||
| On the treatment of diabetes mellitus with glucagon-like peptide-1. | Q54106557 | ||
| Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport | Q57118159 | ||
| Chitosan-Coated Solid Lipid Nanoparticles for Insulin Delivery | Q57570847 | ||
| Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor | Q58448382 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1486-97 | |
| P577 | publication date | 2012-11-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Diabetes Science and Technology | Q15755249 |
| P1476 | title | Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? | |
| P478 | volume | 6 |
| Q90676600 | Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus |
| Q57026289 | Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial |
| Q39790895 | In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy. |
| Q35557405 | Lessons learned from the clinical development of oral peptides |
| Q36127715 | Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats |
| Q34530446 | Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells |
Search more.